CG Oncology (CGON) vs Iovance Biotherapeutics (IOVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Iovance Biotherapeutics (IOVA) has outperformed CG Oncology (CGON) over the past year, gaining 567.6% versus a gain of 43.5%. Iovance Biotherapeutics is the larger company by market cap ($6.62 billion vs $5.66 billion), about 1.2 times the size, while CG Oncology is growing revenue faster (+254.7% vs +60.6%). Iovance Biotherapeutics converts more of its revenue into profit, with a net margin of -148.4% versus -3985.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGON | IOVA |
|---|---|---|
| Share price | $63.82 | $14.62 |
| Market cap | $5.66B | $6.62B |
| 1-day change | +0.89% | +9.84% |
| YTD return | +53.71% | +435.53% |
| 1-year return | +43.54% | +567.58% |
| 5-year return | — | -45.06% |
| EPS (TTM) | $-2.69 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.04M | $263.50M |
| Revenue growth (YoY) | +254.70% | +60.60% |
| Net income (latest FY) | $-161.00M | $-390.98M |
| Gross margin | — | 34.28% |
| Operating margin | -4722.13% | -153.08% |
| Net margin | -3985.02% | -148.38% |
| 52-week high | $80.97 | $15.30 |
| 52-week low | $35.80 | $1.76 |
| Distance from 52-week high | -21.18% | -4.44% |
| Analyst consensus | none | buy |
| Avg. price target upside | +42.71% | -12.45% |
| Average volume | 887.23K | 17.94M |
| Shares outstanding | 88.64M | 452.97M |
| Employees | 142 | 975 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IOVA has outperformed CGON by 524.0 percentage points over the past year.
- Iovance Biotherapeutics is more profitable, keeping -148.4 cents of every revenue dollar as net income versus -3985.0 cents for CG Oncology.
- CG Oncology grew revenue faster in its latest fiscal year (+254.70% vs +60.60%).
About CG Oncology
CGON stock →CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees
About Iovance Biotherapeutics
IOVA stock →Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 975 employees
CGON vs IOVA FAQ
Which is bigger, CG Oncology or Iovance Biotherapeutics?
Iovance Biotherapeutics (IOVA) is larger, with a market capitalization of $6.62B compared with $5.66B for CG Oncology (CGON).
Which stock has performed better over the past year, CGON or IOVA?
IOVA returned +567.58% over the past 12 months, compared with +43.54% for CGON (price return, excluding dividends). Past performance does not predict future results.
Are CG Oncology and Iovance Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.